- News

Asceneuron is awarded Alzheimer’s Drug Discovery Foundation Grant

Alzheimer’s Drug Discovery Foundation (ADDF) awarded a USD 325,000 grant to support the development of Asceneuron’s tau modulators.

- News

Asceneuron featured in BioCentury

Asceneuron is featured in a BioCentury emerging company profile by Emily Cukier-Meisner.

- Press releases

Asceneuron scoops One Nucleus BioNewsRound Award 2015

As announced at Genesis 2015, Asceneuron is this year’s winner of the coveted One Nucleus BioNewsRound Award.

- Press releases

Asceneuron appoints leading experts to Scientific Advisory Board

Asceneuron today announced the appointment of leading experts in the field of neurodegenerative diseases to its newly formed scientific advisory board (SAB): Prof. Christian Haass from Ludwig-Maximilians University (LMU) Munich; Prof. Adam Boxer from University of California, San Francisco (UCSF); and Prof. Günter U. Höglinger from the Technical University of Munich.

- Press releases

Asceneuron strengthens Board of Directors

Asceneuron today announced that Prof. Raymond Hill, former Executive Director, Licensing and External Research, Europe for Merck Sharp and Dohme, has been appointed to the board of directors. In addition, Dr. Franz Hefti, experienced in development of therapeutics for Alzheimer’s disease and former Chief Scientific Officer of Avid Radiopharmaceuticals before its acquisition by Eli Lilly in 2010, has been appointed as special advisor to the board.

- News

Asceneuron wins the Universal Biotech Innovation Prize 2014

Asceneuron wins the Universal Biotech Innovation Prize 2014. Open to young innovative companies, academic and private researchers, the Universal Biotech Innovation Prize aims to acknowledge on an international scale, the most innovative early stage projects in life sciences.

- News

CurePSP awards a research grant to Asceneuron

CurePSP awards a research grant to Asceneuron to study the role of O-linked protein glycosylation in the spread of tau pathology.

- Press releases

Dr. J. Donald deBethizy appointed to the Asceneuron’s Board of Directors

Asceneuron today announced the appointment of Dr. J. Donald deBethizy to its board of directors.

- Event

Asceneuron presents the novel M1-targeting compound ASN-51

Asceneuron presents the novel M1-targeting compound ASN-51 at the 11th International Conference on Alzheimer's and Parkinson's disease held 6-10 March 2013 in Florence, Italy.

- Press releases

Merck Serono announces the creation of Asceneuron

Merck Serono announces the creation of Asceneuron, the third Spin-Off company from its entrepreneur Partnership Program. Asceneuron will develop Merck Serono’s research programs in the area of Alzheimer’s disease.